It seems like ages since President Trump castigated drug company executives for “getting away with murder” and promised to take on the powerful pharma lobby.

While the spotlight has shifted (and the threat of a crackdown has dimmed), the pharma industry still has plenty on its plate. The man charged with pushing the industry’s agenda is Stephen J. Ubl, the president and CEO of the PhRMA trade group. He stopped by the STAT offices in Boston this week to talk about his plans — and the challenges he’s confronting. Here are the highlights:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • You give front page space to Big Pharma’s highest paid Liar? And you have some rookie do the “interview?” Did Ed Silverman throw up? This is not journalism, this is pandering to advertisers. Shame on WHOEVER thought this was a good idea!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy